Interview with Jonathan Zhu, General Manager, Celgene China
Celgene is a relative newcomer to China. What’s the story behind how the company entered the market, and how did you yourself come to manage the local operations? I officially…
Address: No. 222, Huangpu District, Shanghai Yan’an East Road
, Bund Center, 1102 – Room 1104
Zip: 200002 ,China
Tel: +86 216 133 9333
The new base is committed to providing innovative medicines that can really change the life for patients. Our mission is to build a global enterprise based biopharmaceutical, while focusing on the exploration, development, and commercialization of pharmaceutical products for the treatment of cancer and other serious diseases such as immune and inflammatory.
Major medical centers about 300 a number of new base compounds of clinical trials. Compounds of these studies are for blood and solid tumor cancer patients suffering from an incurable research, including multiple myeloma, bone marrow hyperplasia anomaly syndrome, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL ), myelofibrosis, small cell lung cancer and prostate cancer.
As committed to the clinical achievements, we are equally committed to providing patient support, which is the guiding principle of the new base. We believe that all patients should be given the opportunity to benefit from our research. New base by the industry-leading program patients were placed in the first, to provide information, support, and our innovative therapies.
Revlimid
Celgene is a relative newcomer to China. What’s the story behind how the company entered the market, and how did you yourself come to manage the local operations? I officially…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Merck’s $2.13B deal with SciBrunch for KRAS G12D inhibitor SPR2015, Abogen’s $7.78B partnership with Novartis for an mRNA T-cell…
China has rapidly become the world’s leading country for clinical trial volume, alongside the stratospheric growth of its local biotech industry, which now accounts for almost a third of the…
Chinese biotechs are now outpacing multinationals at getting drugs into pivotal trials — but MNCs still win the race to final approval. In this piece from the September 2026 edition…
Excalipoint is betting that the next chapter of T-cell engagers will be written in solid tumours, where the modality is beginning to challenge the boundaries of cancer immunotherapy. Co-Founder, Chairman…
CirCode Biomed is emerging at the forefront of a small but fast-evolving field seeking to turn circular RNA into a new class of medicines. From its roots in pioneering academic…
Chinese pharmaceutical companies are increasingly seeking drug approval in the EU, US, and Australia, beyond the NMPA. Daphne Smyth of Veristat has witnessed this shift firsthand, advising sponsors on data…
For two decades the case for running a clinical trial in Asia was essentially arithmetic: the same study, for less money. That argument has not gone away, but it is…
Our goal is to generate rigorous clinical data demonstrating that these therapies can deliver meaningful and lasting benefits for patients For decades, neurological diseases such as Parkinson’s disease, spinal cord…
China has built one of the world’s most advanced digital health ecosystems — large, fast-moving, and integrated across hospitals, internet platforms, insurers, pharmaceutical companies, and regulators. AI is now embedded…
As the global clinical development landscape becomes more fragmented and competitive, biotechs increasingly need partners that can help them navigate regulatory complexity, identify the right trial locations, and generate meaningful…
Dr Long Jiang is the CEO of GCP ClinPlus, a Chinese CRO with operations in New Jersey. A former cardiovascular surgeon at Peking University People’s Hospital, he shifted into clinical research…
After six years leading the French Healthcare Alliance China, Olivier Dessajan has watched the Franco-Chinese healthcare relationship transform beyond recognition; from a one-way flow of products and partnerships into something…
See our Cookie Privacy Policy Here
